These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

579 related items for PubMed ID: 26937492

  • 1. Olaparib for the treatment of ovarian cancer.
    Bornstein E, Jimeno A.
    Drugs Today (Barc); 2016 Jan; 52(1):17-28. PubMed ID: 26937492
    [Abstract] [Full Text] [Related]

  • 2. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC.
    Expert Opin Investig Drugs; 2016 Jan; 25(5):597-611. PubMed ID: 26899229
    [Abstract] [Full Text] [Related]

  • 3. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    Moore KN, Monk BJ.
    Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
    [Abstract] [Full Text] [Related]

  • 4. The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.
    Nirsimloo R, Gourley C.
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):597-603. PubMed ID: 27115428
    [Abstract] [Full Text] [Related]

  • 5. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
    Miller RE, Ledermann JA.
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
    [Abstract] [Full Text] [Related]

  • 6. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
    Gunderson CC, Moore KN.
    Future Oncol; 2015 Aug; 11(5):747-57. PubMed ID: 25757679
    [Abstract] [Full Text] [Related]

  • 7. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE, Kennedy RD.
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [Abstract] [Full Text] [Related]

  • 8. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.
    Oncotarget; 2017 Jul 18; 8(29):47154-47160. PubMed ID: 28454085
    [Abstract] [Full Text] [Related]

  • 9. Olaparib (Lynparza) for advanced ovarian cancer.
    Med Lett Drugs Ther; 2016 Feb 29; 58(1489):e32-3. PubMed ID: 26938702
    [No Abstract] [Full Text] [Related]

  • 10. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.
    Lorusso D, Tripodi E, Maltese G, Lepori S, Sabatucci I, Bogani G, Raspagliesi F.
    Drug Des Devel Ther; 2018 Feb 29; 12():1501-1509. PubMed ID: 29881257
    [Abstract] [Full Text] [Related]

  • 11. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U.
    Lancet Oncol; 2016 Nov 29; 17(11):1579-1589. PubMed ID: 27617661
    [Abstract] [Full Text] [Related]

  • 12. Olaparib for the treatment of epithelial ovarian cancer.
    McLachlan J, Banerjee S.
    Expert Opin Pharmacother; 2016 Nov 29; 17(7):995-1003. PubMed ID: 26967466
    [Abstract] [Full Text] [Related]

  • 13. Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.
    Frampton JE.
    BioDrugs; 2015 Apr 29; 29(2):143-50. PubMed ID: 25899311
    [Abstract] [Full Text] [Related]

  • 14. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
    Liu JF, Matulonis UA.
    Curr Oncol Rep; 2016 May 29; 18(5):29. PubMed ID: 26984416
    [Abstract] [Full Text] [Related]

  • 15. Olaparib.
    Goulooze SC, Cohen AF, Rissmann R.
    Br J Clin Pharmacol; 2016 Jan 29; 81(1):171-3. PubMed ID: 26344419
    [Abstract] [Full Text] [Related]

  • 16. The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.
    Chen Y, Du H.
    Biomed Pharmacother; 2018 Mar 29; 99():552-560. PubMed ID: 29895102
    [Abstract] [Full Text] [Related]

  • 17. FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
    Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, Sridhara R, Lee E, Tzou A, Philip R, Chiu HJ, Ricks TK, Palmby T, Russell AM, Ladouceur G, Pfuma E, Li H, Zhao L, Liu Q, Venugopal R, Ibrahim A, Pazdur R.
    Clin Cancer Res; 2015 Oct 01; 21(19):4257-61. PubMed ID: 26187614
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
    Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Loman N, Robertson JD, Mann H, Kaufman B.
    Gynecol Oncol; 2016 Feb 01; 140(2):199-203. PubMed ID: 26723501
    [Abstract] [Full Text] [Related]

  • 19. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design.
    Poveda AM, Davidson R, Blakeley C, Milner A.
    Future Oncol; 2019 Nov 01; 15(32):3651-3663. PubMed ID: 31553234
    [Abstract] [Full Text] [Related]

  • 20. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
    Wu L, Zhong L.
    J Med Econ; 2019 Feb 01; 22(2):187-195. PubMed ID: 30522378
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.